Peptides for Weight Loss: What Actually Works

Peptides for weight loss is one of the more confusing categories in current wellness marketing because the evidence levels for different peptides span the entire range from “FDA-approved with massive clinical trial datasets” to “promising preclinical research” to “marketing claims with no real evidence base.” The honest framework starts with GLP-1 receptor agonists (semaglutide and tirzepatide), which are technically peptide-based medications and which have the strongest weight loss evidence of any pharmacological intervention to date. Other peptides have legitimate adjunctive roles in metabolic health and body composition, but they are not GLP-1 alternatives in any meaningful sense. This guide covers the evidence-tiered approach to peptides for weight loss and clarifies which patients benefit from which peptides for which goals.

GLP-1 Agonists: The Gold Standard, and They Are Peptides

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the most clinically studied and effective weight loss peptides. They are technically peptide medications, though the public conversation often does not categorize them as “peptide therapy” in the wellness sense because they are FDA-approved pharmaceuticals dispensed through standard prescription channels. The clinical reality is that they produce roughly 15 to 25 percent body weight reduction over 12 to 18 months of consistent use in appropriate patients, which is dramatically more than any other peptide intervention can claim.

The mechanism is GLP-1 receptor agonism. Native GLP-1 (glucagon-like peptide-1) is an incretin hormone produced by L-cells in the gut in response to food intake. It signals satiety, slows gastric emptying, and stimulates insulin release in glucose-dependent fashion. Semaglutide is a long-acting GLP-1 analog. Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic peptide) receptor agonist, with a PubMed report on the SURMOUNT-1 tirzepatide trial documenting weight reduction outcomes that have generally exceeded semaglutide’s in head-to-head data. The FDA announcement on semaglutide approval for chronic weight management documented the trial data supporting approval and the side effect profile clinicians monitor during use.

For patients seeking peptide-based weight loss, the GLP-1 conversation should come first. The Tactus Health weight loss program is built around GLP-1 protocols paired with the lifestyle, nutritional, and sometimes hormonal support that produces durable results. Patients pursuing other peptides for weight loss without first considering whether GLP-1 is appropriate are typically passing on the most evidence-based intervention in favor of less-supported alternatives.

Sermorelin and Growth Hormone Secretagogues

The GH-axis peptides (sermorelin, CJC-1295, ipamorelin) have a legitimate but specific role in weight loss, particularly for body composition and lean mass preservation. The role is adjunctive rather than primary. These peptides do not produce weight loss in the magnitude that GLP-1 medications produce, and they are not appropriate substitutes for GLP-1 protocols in patients who would benefit from GLP-1 therapy.

Where GH-axis peptides earn their place in weight loss protocols is in two specific situations. The first is body composition during active weight loss, where GH support helps preserve lean muscle mass while body fat is being reduced. Significant weight loss without GH support tends to produce loss of both fat and muscle in roughly a 75/25 ratio; with adequate GH-axis function and appropriate protein intake, the ratio shifts toward more selective fat loss. The second is the “stuck-on-the-last-10-pounds” patient who has lost most of their target weight on GLP-1 or other interventions but cannot lose the final visceral and stubborn fat that the GH-axis particularly affects.

For patients on GLP-1 therapy who are also dealing with the body composition concerns common in midlife (declining muscle mass, increased visceral fat that is harder to lose), combining GLP-1 with GH-axis peptides is a reasonable protocol. The two work through different mechanisms and complement each other rather than substituting for each other.

AOD-9604: The Research Reality

AOD-9604 is a synthetic peptide derived from a fragment of the human growth hormone molecule (specifically, amino acids 177-191). It was originally developed as a potential anti-obesity therapy based on preclinical evidence that this fragment retained the lipolytic (fat-mobilizing) effects of GH without the growth-promoting effects. The early animal data and small early-phase human studies were promising. However, larger randomized controlled trials in humans failed to demonstrate clinically meaningful weight loss compared to placebo, and the development program for AOD-9604 as an anti-obesity drug was discontinued.

The current marketing of AOD-9604 in wellness and peptide therapy contexts does not generally acknowledge this trial history. The honest position is that AOD-9604 had a fair shot at demonstrating efficacy in proper trials, did not meet the primary endpoints, and is therefore not supported by the kind of evidence base that would justify routine use. Patients pursuing AOD-9604 for weight loss are working with a peptide that did not pass its own efficacy testing, which is meaningfully different from peptides that have not yet been tested.

This does not mean AOD-9604 is harmful. The safety profile in observed clinical use has been favorable. It does mean the case for using it as a primary weight loss intervention is weak, particularly when GLP-1 medications with much stronger evidence are available for the same goal.

5-Amino-1MQ: Emerging Research

5-Amino-1MQ is an inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme involved in cellular metabolism that becomes overactive in obesity and insulin resistance. The preclinical research on 5-Amino-1MQ in animal models of obesity and insulin resistance has shown promising metabolic effects: reduced fat mass, improved insulin sensitivity, and metabolic markers consistent with mobilization of stored fat. The mechanism is interesting because it acts at the cellular metabolic level rather than the appetite-regulation level where GLP-1 works.

The honest gap is that 5-Amino-1MQ has not yet been studied in adequate human clinical trials. The animal data is encouraging but not yet translated. Patients pursuing 5-Amino-1MQ are working with a peptide where the human evidence does not yet exist. This is a different position than AOD-9604 (which failed human trials) or GLP-1 medications (which succeeded in extensive trials), and it should be discussed with patients honestly rather than positioned as an established weight loss intervention.

For patients particularly interested in the metabolic-restoration angle and willing to work with a peptide at this evidence level, 5-Amino-1MQ may be considered. For patients seeking established weight loss intervention, the GLP-1 protocols remain the appropriate first choice.

The Practical Framework for Peptides for Weight Loss

The approach used at Tactus Health for weight loss peptide protocols is to start from the patient’s specific goals and evidence preferences and work back to the appropriate peptide protocol. For most patients seeking meaningful weight loss, the conversation starts with GLP-1 evaluation. The clinical workup determines whether GLP-1 therapy is appropriate (cardiovascular history, GI history, current medications, comorbidities), and if so, the protocol is built around the appropriate GLP-1 medication paired with the necessary lifestyle and nutritional support.

For patients on GLP-1 therapy who also have meaningful body composition goals or stubborn visceral fat that GLP-1 alone is not addressing, adding GH-axis peptide support during the active weight loss phase is reasonable. This is paired with appropriate protein intake (typically 1.0 to 1.2 grams per pound of target body weight) and resistance training to ensure the GH support translates to muscle preservation rather than just metabolic effects.

For patients with specific objections to GLP-1 therapy or specific clinical reasons it is not appropriate, the conversation about other peptides becomes relevant but is approached with honesty about the evidence levels. Other peptides may have a role, but they should not be sold as GLP-1 alternatives because the evidence base does not support that positioning.

What Peptide Therapy Cannot Replace

The honest framing for any peptide-based weight loss intervention is that peptides amplify what the patient is doing with diet, training, sleep, and stress management; they do not substitute for those fundamentals. Patients pursuing peptide weight loss without addressing the lifestyle dimensions tend to see disappointing results regardless of which peptide they use. GLP-1 medications produce dramatic weight loss in many patients, but the patients who maintain the loss long-term are typically those who also developed the eating, training, and lifestyle patterns that support the lower body weight after the medication is tapered.

The same principle applies to GH-axis peptides for body composition. Adding sermorelin or the CJC-1295 ipamorelin stack to a patient who is not training, not eating adequate protein, and not sleeping enough produces minimal observable change. Adding the same peptides to a patient who is doing those things consistently produces meaningful body composition improvement. The peptides are tools that amplify the work; they are not substitutes for the work itself.

Common Patient Questions

Are GLP-1 medications considered peptide therapy? Technically yes, since semaglutide and tirzepatide are peptide-based medications. The wellness conversation often does not categorize them as “peptide therapy” because they are FDA-approved pharmaceuticals dispensed through standard channels rather than compounded peptides used off-label. The categorization is more semantic than pharmacological.

Can I use peptides instead of GLP-1 medications for weight loss? The honest answer is that no other peptide approaches the weight loss efficacy of GLP-1 medications in current evidence. Patients pursuing other peptides as GLP-1 alternatives are typically passing on the most evidence-based intervention. There may be specific clinical reasons GLP-1 is not appropriate for an individual patient, in which case other approaches become more relevant, but the framework starts with GLP-1 evaluation.

Will sermorelin help me lose weight? Sermorelin’s role in weight loss is adjunctive rather than primary. It supports body composition (fat loss with lean mass preservation) when combined with appropriate diet and training, but the magnitude of the effect on weight specifically is modest. For body composition optimization during weight loss or maintenance, sermorelin is reasonable. For primary weight loss intervention, GLP-1 remains the better choice.

What about combining GLP-1 with sermorelin? This combination is reasonable and increasingly common. GLP-1 produces the primary weight loss effect; sermorelin or the GH-axis stack helps preserve lean mass and supports body composition during active weight loss. The two work through different mechanisms and do not interact adversely. This combination is part of the standard Tactus Health protocol for patients with both significant weight loss goals and body composition concerns.

Can I use AOD-9604 if I just want to support my weight loss? The evidence does not support AOD-9604 as an effective weight loss intervention based on its trial history. Patients who want adjunctive support for weight loss are better served by sermorelin, by ensuring adequate protein and training, and by addressing the broader metabolic and hormonal picture rather than by adding AOD-9604 specifically.

The Bottom Line

Peptides for weight loss occupy a confusing landscape because the marketing flattens the evidence levels in a way that is misleading to patients trying to make informed decisions. The clearest framework starts with the recognition that GLP-1 medications are peptide-based, are the most evidence-based weight loss intervention currently available, and should be the first consideration for most patients with significant weight loss goals. GH-axis peptides have a real but adjunctive role for body composition during weight loss. AOD-9604, 5-Amino-1MQ, and other “weight loss peptides” being marketed have evidence levels that do not support their positioning as primary interventions. The right approach is to start from the patient’s specific goals and evidence preferences and build the protocol from there, rather than picking peptides based on which sounds most innovative. The evaluation determines what fits the picture.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Co-Founder & Medical Director at Tactus Health. Dual board-certified, with clinical focus on peptide therapy, hormone optimization, and medical weight loss. Sugar Hill, GA and telehealth for Georgia patients.